morning thank stand welcome abbott third quarter earn conference call operator instruction call record abbott exception participant question question answer session entire call include question answer session material copyright abbott record rebroadcast without abbott express write permission would like introduce vice president investor relation license acquisition vice president investor relation license acquisition good morning thank join today ford president chief executive officer executive vice president finance chief financial officer provide open remark follow comment take question start statement make today forward look purpose private security litigation reform include expect financial result abbott caution forward look statement subject risk uncertainty cause actual result differ materially indicate forward look statement economic competitive governmental technological factor affect abbott operation discuss item annual report form year abbott undertake obligation release publicly revision forward look statement result subsequent event development except require today conference call past financial measure help investor understand abbott ongoing business performance financial measure reconcile comparable financial measure earn news release regulatory find today available website abbott unless otherwise note commentary sale growth refer organic sale growth exclude impact foreign exchange turn call ford president chief executive good morning everyone thank join today report result another strong quarter ongoing earn share reflect nearly growth compare last year sale increase organic basis exclude test relate sale total billion quarter organic sale increase versus last year since start pandemic diversify healthcare business continue prove highly resilient even case rate surge geography third quarter strong growth consumer face business establish pharmaceutical diabetes care mitigate modest impact surge certain area hospital base business consistent theme throughout pandemic evidence increase total company sale exclude test organic basis first nine month year compare pandemic baseline highlight growth real simply function easy comp versus last year result strong performance outlook today increase full year adjust earn share guidance range reflect nearly growth compare last year summarize third quarter result turn call start nutrition sale increase compare last year strong growth quarter lead pediatric international adult nutrition pediatric nutrition sale grow quarter lead strong growth continue share gain infant formula toddler portfolio sale market lead rehydration brand grow strong double digit drive market uptake several recently launch product investment make direct consumer promotion adult nutrition sale grow quarter include teen growth internationally continue strong demand ensure brand include user enter category exist customer increase usage turn diagnostics sale increase overall exclude test relate sale quarter delta variant spread case surge particularly demand test increase significantly notably rapid test total quarter sell million test globally ship billion test since start pandemic last several month learn vaccine powerful tool solution need global fight virus test particularly rapid test affordable easy important companion vaccine therapeutic abbott establish global leadership position rapid test include supply capacity million test month move establish pharmaceutical sale grow drive strong execution steady cadence product introduction strong sale performance quarter broad base across several country include double digit growth lead overall sale growth emerge market lastly cover medical device sale grow quarter compare last year compare pandemic sale third quarter strong performance quarter lead double digit growth rhythm management structural heart heart failure diabetes care structural heart continue enhance portfolio large grow market recent approval close leave atrial appendage heart help reduce risk stroke people atrial fibrillation transcatheter aortic valve replacement heart failure announce result guide trial system many recent ongoing clinical trial across healthcare industry portion trial overlap pandemic adjust impact demonstrate reduction heart failure hospitalization file label expansion base trial data middle year quarter also attractive growth platform vascular device portfolio acquisition walk vascular commercial stage company minimally invasive thrombectomy system call remove peripheral blood peripheral thrombectomy large high growth area leverage exist commercial presence wrap diabetes care strong growth lead sale nearly billion quarter user bring total global user base million user summary continue achieve strong balance growth across major business fuel strong execution steady cadence product test particularly test remain important companion vaccine therapeutic abbott establish strong leadership position area base strength performance outlook raise guidance year reflect growth nearly compare last year turn call result outlook year detail executive vice president finance chief financial mention earlier please note reference sale growth rate unless otherwise note organic basis consistent previous guidance turn result sale third quarter increase organic basis lead strong performance across business along global test relate sale billion quarter exclude test relate sale organic sale growth versus last year compare third quarter foreign exchange favorable year year impact third quarter sale result total report sale growth quarter regard aspect quarter adjust gross margin ratio sale adjust investment sale adjust expense sale third quarter adjust rate reflect adjustment align year date rate revise full year effective rate forecast revise full year forecast modestly higher estimate provide shift business geographic income turn outlook fourth quarter forecast billion billion test relate sale forecast organic sale growth exclude test relate sale double digit versus last year base current rate would expect exchange unfavorable impact around half fourth quarter report sale open call question